Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra.
Loh, N. K. 1; Lucas, M. 2,3; Fernandez, S. 4; Prentice, D. 1
[Miscellaneous Article]
Internal Medicine Journal.
42(12):1358-1362, December 2012.
(Format: HTML, PDF)
: A previously healthy 20-year-old man presented with adult Still disease (ASD). He developed life-threatening macrophage activation syndrome (MAS), which was refractory to standard immunosuppression but responded dramatically to the IL-1 receptor antagonist anakinra. Subsequent immunological investigations included assessment of the perforin expression of natural killer (NK) cells and CD8 T cells, which confirmed MAS.
Copyright (C) 2012 Blackwell Publishing Ltd.